Bedel Financial Consulting’s Regeneron Pharmaceuticals REGN Stock Holding History

Bedel Financial Consulting’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15	Closed	-$10K	–	725
2022 Q1	$10K	Hold	15	–	–	﹤0.01%	675
2021 Q4	$9K	Hold	15	–	–	﹤0.01%	701
2021 Q3	$9K	Hold	15	–	–	﹤0.01%	694
2021 Q2	$8K	Hold	15	–	–	﹤0.01%	708
2021 Q1	$7K	Hold	15	–	–	﹤0.01%	696
2020 Q4	$7K	Hold	15	–	–	﹤0.01%	609
2020 Q3	$8K	Sell	15 -5	-25%	-$3.03K	﹤0.01%	547
2020 Q2	$12K	Hold	20	–	–	0.01%	468
2020 Q1	$10K	Buy	20 +5	+33%	+$2.06K	0.01%	480
2019 Q4	$6K	Sell	15 -24	-62%	-$8.07K	﹤0.01%	566
2019 Q3	$11K	Hold	39	–	–	0.01%	472
2019 Q2	$12K	Hold	39	–	–	0.01%	467
2019 Q1	$16K	Hold	39	–	–	0.01%	418
2018 Q4	$15K	Hold	39	–	–	0.01%	403
2018 Q3	$15K	Hold	39	–	–	0.01%	423
2018 Q2	$13K	Buy	39 +24	+160%	+$7.51K	0.01%	447
2018 Q1	$5K	Buy	+15	New	+$5.22K	﹤0.01%	543

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bedel Financial Consulting's REGN Position: Q2 2022 in Review

Bedel Financial Consulting sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 15 shares — an estimated $10K sold.

Bedel Financial Consulting first reported a position in REGN in Q1 2018 and held it in 17 quarters. The position peaked at $16K in Q1 2019. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

Bedel Financial Consulting reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Bedel Financial Consulting sold 15 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $10K.
Bedel Financial Consulting first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 17 quarters.
Bedel Financial Consulting's Regeneron Pharmaceuticals position peaked at $16K in Q1 2019.
1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.